Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
VOR
Upturn stock ratingUpturn stock rating

Vor Biopharma Inc (VOR)

Upturn stock ratingUpturn stock rating
$1.98
Last Close (24-hour delay)
Profit since last BUY38.46%
upturn advisory
Consider higher Upturn Star rating
BUY since 32 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: VOR (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $1.18

1 Year Target Price $1.18

Analysts Price Target For last 52 week
$1.18 Target price
52w Low $0.13
Current$1.98
52w High $3.29

Analysis of Past Performance

Type Stock
Historic Profit -20.3%
Avg. Invested days 34
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 250.75M USD
Price to earnings Ratio -
1Y Target Price 1.18
Price to earnings Ratio -
1Y Target Price 1.18
Volume (30-day avg) 5
Beta 2.06
52 Weeks Range 0.13 - 3.29
Updated Date 08/15/2025
52 Weeks Range 0.13 - 3.29
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -13.68

Earnings Date

Report Date 2025-08-14
When -
Estimate -0.2243
Actual -12.56

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -132.36%
Return on Equity (TTM) -125.43%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 50182215
Price to Sales(TTM) -
Enterprise Value 50182215
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.09
Shares Outstanding 126640000
Shares Floating 47588511
Shares Outstanding 126640000
Shares Floating 47588511
Percent Insiders 42.84
Percent Institutions 45.37

ai summary icon Upturn AI SWOT

Vor Biopharma Inc

stock logo

Company Overview

overview logo History and Background

Vor Biopharma Inc. was founded in 2016. It is a clinical-stage cell therapy company pioneering engineered hematopoietic stem and progenitor cells (HSPCs) to create next-generation, off-the-shelf therapies for hematological malignancies. Significant milestones include IND clearance for lead candidate VOR33 and initiation of clinical trials.

business area logo Core Business Areas

  • Engineered HSPCs: Vor Biopharma's core business revolves around developing and commercializing engineered HSPCs. They are focused on making allogeneic stem cell transplants safer and more effective for patients with blood cancers.
  • VOR33 Clinical Program: The clinical trial for VOR33, their lead product, focuses on acute myeloid leukemia (AML). It's designed to deplete CD33-expressing cells to enable safer and more effective transplantation.

leadership logo Leadership and Structure

Robert Ang, M.D., Ph.D. is the President and Chief Executive Officer. The company has a typical structure for a clinical-stage biotech company, with departments focused on research, clinical development, manufacturing, and corporate functions.

Top Products and Market Share

overview logo Key Offerings

  • VOR33: VOR33 is Vor Biopharma's lead product candidate, engineered HSPCs designed to be insensitive to Mylotarg (gemtuzumab ozogamicin), an anti-CD33 antibody-drug conjugate. It is currently in clinical trials for AML. Market share data is not yet applicable as it is pre-commercial. Competitors developing AML treatments include AbbVie (Venclexta), Novartis (Rydapt), and other companies developing stem cell transplantation technologies.

Market Dynamics

industry overview logo Industry Overview

The industry is characterized by intense research and development, high regulatory hurdles, and a competitive landscape. Advances in cell and gene therapy are creating new opportunities for treating previously untreatable diseases. There is a growing demand for more effective and safer treatments for hematological malignancies.

Positioning

Vor Biopharma is positioned as an innovator in engineered HSPC technology, seeking to overcome limitations of traditional stem cell transplantation. Its competitive advantage lies in its specific targeting of CD33-expressing cells and its potential to improve outcomes for AML patients.

Total Addressable Market (TAM)

The global AML market is expected to reach approximately $3.5 billion by 2028. Vor Biopharma is positioned to capture a portion of this market through its novel approach to stem cell transplantation.

Upturn SWOT Analysis

Strengths

  • Novel engineered HSPC technology
  • Targeted approach to CD33-expressing cells
  • Strong intellectual property position
  • Experienced management team

Weaknesses

  • Clinical-stage company with no revenue-generating products
  • High cash burn rate
  • Reliance on clinical trial success
  • Small market capitalization

Opportunities

  • Successful clinical trials and regulatory approval of VOR33
  • Expansion of platform technology to other hematological malignancies
  • Partnerships with pharmaceutical companies
  • Potential for acquisition by a larger company

Threats

  • Clinical trial failures
  • Regulatory setbacks
  • Competition from other cell therapy companies
  • Development of alternative AML treatments

Competitors and Market Share

competitor logo Key Competitors

  • CRSP
  • EDIT
  • BLUE

Competitive Landscape

Vor Biopharma faces competition from other companies developing cell and gene therapies for hematological malignancies. Its advantage lies in its unique approach to engineered HSPCs and its focus on CD33 depletion.

Growth Trajectory and Initiatives

Historical Growth: Vor Biopharma's growth has been driven by the advancement of its VOR33 clinical program and the expansion of its engineered HSPC platform.

Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approval of VOR33. Analyst estimates vary widely, reflecting the uncertainty associated with drug development.

Recent Initiatives: Recent initiatives include advancing the VOR33 Phase 1/2 clinical trial, expanding the company's manufacturing capabilities, and exploring potential partnerships.

Summary

Vor Biopharma is a clinical-stage company with a promising engineered HSPC technology targeting AML. Its success is highly dependent on the outcome of clinical trials for VOR33. The company has a strong intellectual property position but faces the risks associated with drug development, including regulatory hurdles and competition. The company needs to focus on making clinical advances in trials.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (SEC)
  • Analyst reports
  • Industry news sources
  • Vor Biopharma Investor Relations website

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Vor Biopharma Inc

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2021-02-05
Chairman & CEO Dr. Jean-Paul Kress M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 159
Full time employees 159

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.